Lanreotide: What the Evidence Actually Shows

Lanreotide is octreotide's closest sibling: the same drug class — a somatostatin analog — with a mechanism close enough that its own FDA label describes it as "believed to be similar to that of natural somatostatin," the identical language octreotide's label uses about itself. But it is a genuinely different molecule with its own separate FDA approval, its own indication set, and — the most practical difference for anyone comparing the two — a fundamentally different product design. Where octreotide's long-acting version requires a fixed clinician-mixed kit, lanreotide's is a true ready-to-inject prefilled syringe. This article covers what actually distinguishes them, not just what they share.

A real, separate FDA approval — not a variant of octreotide

Somatuline Depot was approved August 30, 2007, under NDA022074, sponsored by Ipsen Pharma — a Type 1 New Molecular Entity approval, confirmed directly against openFDA's Drugs@FDA database¹. That's a genuinely distinct approval from octreotide's, not a line extension: lanreotide is its own molecule, its own NDA, its own sponsor. Independently cross-checked against DailyMed's structured-product-label index: one current, live label, most recently updated October 2024¹.

Three indications — one shared with octreotide, two with real distinctions

Somatuline Depot's current label lists three indications: acromegaly (the original 2007 approval), gastroenteropancreatic neuroendocrine tumors (GEP-NETs, specifically "to improve progression-free survival"), and carcinoid syndrome². The acromegaly indication is the one lanreotide shares squarely with octreotide. The GEP-NET indication is where the two diverge in a way worth naming precisely: it's framed around progression-free survival — a real antitumor claim — while octreotide's own Sandostatin Injection label explicitly states its own pivotal trials did NOT show that kind of effect. That's a genuine, checkable difference in what each drug's own approved evidence base actually supports, not a difference in marketing emphasis.

The GEP-NET indication traces to a real, substantial trial: CLARINET, a randomized, double-blind, placebo-controlled, multinational study of 204 patients with grade 1 or 2, nonfunctioning gastroenteropancreatic neuroendocrine tumors, comparing lanreotide 120 mg every 28 days against placebo for up to 96 weeks³. The result was a real, substantial effect: median progression-free survival was not reached in the lanreotide group, versus 18.0 months with placebo (hazard ratio 0.47, 95% CI 0.30-0.73, P<0.001)³. At 24 months, 65.1% of lanreotide-treated patients remained progression-free, versus 33.0% on placebo³. There was no significant difference in overall survival or quality of life between groups, and the most common treatment-related adverse event was diarrhea (26% lanreotide vs. 9% placebo)³ — a real, well-powered trial behind a real antitumor claim, reported here at the precision the trial itself supports rather than rounded into "lanreotide treats cancer."

The dosage form is the real practical difference from octreotide

This is where lanreotide and octreotide diverge most for anyone actually comparing them. Somatuline Depot's own DOSAGE FORMS AND STRENGTHS section is direct: it ships as a "sterile, single-dose, prefilled syringe" containing "a white to pale yellow, semi-solid formulation," available in 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL strengths⁴. There is no lyophilized powder, no vial, and no diluent of any kind — the syringe already contains the final, ready-to-inject gel. That's a meaningfully simpler product than octreotide's own long-acting version, Sandostatin LAR Depot, which at least requires mixing a lyophilized vial with a fixed diluent syringe before every injection. Lanreotide skips that step entirely.

What lanreotide does share with octreotide's depot version is who gives the injection and how often: "SOMATULINE DEPOT is intended for administration by a healthcare provider," given by deep subcutaneous injection in the superior external quadrant of the buttock, once every 4 weeks⁴. Recommended dosing is 90 mg every 4 weeks for acromegaly (adjusted based on GH/IGF-1 response) and 120 mg every 4 weeks for GEP-NETs or carcinoid syndrome⁴.

Why this site doesn't have a lanreotide reconstitution calculator

Because there's genuinely nothing to reconstitute. Every approved Somatuline Depot strength ships as a sealed, single-dose, prefilled syringe of ready-to-inject gel — no vial, no diluent, no mixing step for a calculator to model. A direct check of this site's own provider records ("sells.ts" and "other-compounds.ts") found zero mentions of lanreotide or Somatuline among reviewed providers — it is a real, prescription-only FDA drug, not a compounded product on this site's roster.

What this means if you're considering it

Lanreotide is a real, separately-FDA-approved somatostatin analog — octreotide's closest sibling in mechanism, but its own molecule with its own approval history, its own indication set (including a real, trial-backed progression-free-survival claim for GEP-NETs that octreotide's own label doesn't carry), and a genuinely simpler prefilled-syringe delivery than octreotide's clinician-mixed depot kit. Like octreotide, it's administered by a healthcare provider, not self-injected, and no reviewed provider on this site sells it. For the full contrast — including how both compare to the growth-hormone-STIMULATING peptides this site otherwise covers — see our octreotide evidence review.